We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences’ (GILD - Free Report) experimental coronavirus candidate, Veklury (remdesivir), has been recommended for approval by the European Medicines Agency (EMA)’s human medicines committee (CHMP).
The CHMP has recommended granting a conditional marketing authorization to Veklury for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen.
Remdesivir is the first medicine against COVID-19 to be recommended for authorization in the EU.
The committee reviewed the data in an exceptionally short timeframe through a rolling review procedure, which is generally used by the EMA during public health emergencies to assess data as they become available. This data primarily comprised data from the study NIAID-ACTT-1, sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), along with supporting data from other studies on remdesivir.
This study evaluated the effectiveness of a planned 10-day course of remdesivir in more than 1,000 hospitalized COVID-19 patients compared with placebo and the main measure of effectiveness was patients’ time to recovery. The study showed that patients treated with remdesivir recovered after about 11 days compared with 15 days for patients given placebo.
Gilead’s shares have rallied 18.4% in the year so far compared with the industry’s growth of 13.6%. In fact, remdesivir is pioneering the race for a possible treatment of this deadly virus.
The FDA granted remdesivir an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19, given the severity of the pandemic.
It was recently granted regulatory approval in Japan under an exceptional approval pathway.
While a potential approval of remdesivir will be a significant boost, there is uncertainty regarding the drug’s profitability in the long run.
Given the alarming levels of spread and severity, some approved drugs are being tested to see if they are effective in treating infected patients.
Roche (RHHBY - Free Report) too initiated a late-stage study on its arthritis drug, Actemra/RoActemra, in combination with remdesivir in hospitalized patients with severe COVID-19 pneumonia.
Alexion is evaluating its rare disease drug, Ultomiris (ravulizumab-cwvz), for the COVID-19 infection.
Incyte (INCY - Free Report) initiated RUXCOVID, a global, randomized, double-blind, placebo-controlled phase III study, evaluating the efficacy and safety of Jakafi plus SoC in patients 12 years and above with COVID-19-associated cytokine storm.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Shutterstock
Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation
Gilead Sciences’ (GILD - Free Report) experimental coronavirus candidate, Veklury (remdesivir), has been recommended for approval by the European Medicines Agency (EMA)’s human medicines committee (CHMP).
The CHMP has recommended granting a conditional marketing authorization to Veklury for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen.
Remdesivir is the first medicine against COVID-19 to be recommended for authorization in the EU.
The committee reviewed the data in an exceptionally short timeframe through a rolling review procedure, which is generally used by the EMA during public health emergencies to assess data as they become available. This data primarily comprised data from the study NIAID-ACTT-1, sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), along with supporting data from other studies on remdesivir.
This study evaluated the effectiveness of a planned 10-day course of remdesivir in more than 1,000 hospitalized COVID-19 patients compared with placebo and the main measure of effectiveness was patients’ time to recovery. The study showed that patients treated with remdesivir recovered after about 11 days compared with 15 days for patients given placebo.
Gilead’s shares have rallied 18.4% in the year so far compared with the industry’s growth of 13.6%. In fact, remdesivir is pioneering the race for a possible treatment of this deadly virus.
The FDA granted remdesivir an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19, given the severity of the pandemic.
It was recently granted regulatory approval in Japan under an exceptional approval pathway.
While a potential approval of remdesivir will be a significant boost, there is uncertainty regarding the drug’s profitability in the long run.
Given the alarming levels of spread and severity, some approved drugs are being tested to see if they are effective in treating infected patients.
Roche (RHHBY - Free Report) too initiated a late-stage study on its arthritis drug, Actemra/RoActemra, in combination with remdesivir in hospitalized patients with severe COVID-19 pneumonia.
Alexion is evaluating its rare disease drug, Ultomiris (ravulizumab-cwvz), for the COVID-19 infection.
Incyte (INCY - Free Report) initiated RUXCOVID, a global, randomized, double-blind, placebo-controlled phase III study, evaluating the efficacy and safety of Jakafi plus SoC in patients 12 years and above with COVID-19-associated cytokine storm.
The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>